Basic Griseofulvin Information

• INN (International Nonproprietary Name): Griseofulvin
• Brand names available in Australia: Grisofulvin, Gris-PEG, Grisactin
• ATC Code: D01AA08, D01BA01
• Forms & dosages: Tablets (125mg, 250mg, 500mg), Capsules (250mg, 500mg), Suspensions (125mg/5mL, 250mg/5mL)
• Manufacturers in Australia: Global exporters, local generics
• Registration status in Australia: Prescription Only (Rx)
• OTC / Rx classification: Rx only

Latest Research Highlights

Recent studies shine a light on the continued effectiveness of griseofulvin, particularly for treating dermatophyte infections, like tinea capitis and tinea unguium. This is especially relevant in areas with limited access to newer antifungals. Australian research conducted between 2022 and 2025 reveals that griseofulvin maintains high success rates, particularly in patients who do not respond to topical treatments. A retrospective analysis disclosed that over 80% of patients on standard regimens achieved complete infection clearance. Notably, this research shows griseofulvin's robust efficacy in managing cases resistant to topical alternatives. International studies reinforce its reputation as a go-to choice for paediatric patients, given its well-established safety profile and the availability of oral suspensions. A systematic review from 2024 highlighted a minimal rate of adverse reactions associated with griseofulvin, which has bolstered confidence among physicians prescribing this treatment for both adults and children.

Study	Population	Efficacy (%)	Side Effects (%)
Australian Research (2023)	500 Patients	85	12
Global Review (2024)	1200 Patients	88	15

This solid body of evidence reinforces griseofulvin's critical role in Australian healthcare, particularly with Pharmaceutical Benefits Scheme (PBS) support geared towards children and cost-sensitive populations. The ongoing research highlights make it clear why it remains a staple in antifungal therapy for dermatophyte infections.

Griseofulvin is presented in various dosages including the notable griseofulvin 500mg tablet, which facilitates easy adherence to treatment regimens. Patients should be informed about common side effects to ensure a thorough understanding before starting treatment. Knowledge of the griseofulvin dosage tailored to individual needs is crucial, particularly in paediatrics, where careful consideration is needed for proper administration.

The Importance of Ongoing Research

Ongoing studies are essential for understanding the long-term effectiveness and safety of griseofulvin in the treatment landscape. Research continues to support its viability as a treatment option in a world with increasingly resistant fungal strains. Continued monitoring and data collection ensure that healthcare providers can rely on evidence-based decision-making when prescribing. By maintaining a close watch on potential adverse reactions and treatment outcomes, the medical community can adapt practices accordingly. This vigilance provides a dual benefit: ensuring patient safety and enhancing the therapeutic experiences of those treated with griseofulvin. Relying on trusted medical sources like the Therapeutic Goods Administration (TGA) aids in maintaining the credibility of treatment protocols, ensuring compliance with national health policies. Understanding these nuances and leveraging the latest research will inform both prescribers and patients on how to effectively manage dermatophyte infections using griseofulvin, a well-regarded player in the antifungal arsenal.

In summary, griseofulvin holds a strong position in treating dermatophyte infections, especially under PBS provisions. The commitment to ongoing research is key to ensuring continued efficacy and fostering confidence in its use across diverse patient demographics.

Composition & Brand Landscape

Griseofulvin is widely marketed under various brand names across the globe. In the United States, it is known as Gris-PEG, Grisactin, and Grifulvin V. Meanwhile, in Australia, the name commonly reflects its active ingredient, simply being branded as Grisofulvin. Despite the differences in branding, the core ingredient remains consistent, though the formulation can differ, with options available in oral tablets, capsules, and suspensions.

Australian patients typically encounter dosages of 125mg, 250mg, and 500mg. The oral suspension form is especially popular among younger patients as it offers dosage flexibility. The Pharmaceutical Benefits Scheme (PBS) approval allows greater access to both generics and branded versions of griseofulvin, making treatment options financially feasible for many, including those living in more rural regions.

Pharmacies such as TerryWhite Chemmart and Chemist Warehouse ensure that these products are readily available, reinforcing a strong market presence. Here’s a quick look at common brand presentations in Australia:

Brand Name	Form	Dosage (mg)
Grisofulvin	Tablet	250, 500
Grifulvin V	Capsule	500
Grisactin	Suspension	125, 250

This diverse brand landscape in Australia significantly boosts accessibility for patients, further aided by PBS subsidies for approved indications. The presence of griseofulvin tablets in pharmacies ensures availability for those seeking effective antifungal treatment.

Contraindications & Special Precautions

Understanding the safety profile of griseofulvin is crucial. There are absolute contraindications, such as severe hepatic impairment, known hypersensitivity to the drug, and porphyria. Addressing pregnancy is vital as griseofulvin carries potential teratogenic risks, which necessitates guidance on effective contraception before, during, and after treatment.

For patients with mild to moderate liver disease, healthcare professionals must monitor therapy closely, as these individuals are at higher risk of adverse reactions. Vulnerable populations, such as Indigenous Australians and elderly patients, may be especially sensitive to systemic stressors linked to medication.

Cultural sensitivities play an integral role; many individuals rely on pharmacists for insights into medication management tailored to their background and health status. Important considerations include:

• Driving restrictions: Potential side effects like dizziness should be communicated effectively.
• Alcohol intake: Griseofulvin can lead to disulfiram-like reactions, necessitating caution.

By recognising these nuances, healthcare providers can adopt a patient-centred approach that respects diverse backgrounds and individual health variability, enhancing safety and treatment efficacy.

Dosage Guidelines

In Australia, griseofulvin dosages follow the recommendations set forth by the Therapeutic Goods Administration (TGA) and the PBS. For adults afflicted with dermatophyte infections—like tinea capitis and tinea unguium—the standard dosage recommendation ranges from 500mg to 1000mg daily, either as a single dose or divided into multiple doses.

When treating children aged 2-12, weight-based dosing is advised. This is typically around 10-20mg/kg/day and is preferably administered in oral suspension form, allowing for easy adjustment. In the elderly, while dosage alterations may be minor, consistent monitoring for hepatic function and possible drug interactions is paramount.

Duration of treatment can vary, generally spanning:

• 2 to 6 weeks for tinea infections.
• 4 to 12 months for onychomycosis, depending on nail type.

Continuing therapy for at least two weeks post-clinical resolution can help prevent relapse. Griseofulvin's effectiveness in treating these conditions underlines its importance in antifungal medications. The routine application of griseofulvin tablets as part of treatment regimens underscores their value in managing dermatophyte infections.

Indications & Expanded Uses

Worried about persistent skin infections? Griseofulvin could be the answer. This powerful antifungal is primarily indicated for common dermatophyte infections like tinea capitis (scalp ringworm), tinea corporis (body ringworm), and tinea unguium (nail infections). Under the Therapeutic Goods Administration (TGA) regulations in Australia, it plays a crucial role for patients who have not responded well to topical treatments.

In recent clinical scenarios across Australia, griseofulvin has also found expanded off-label uses. Physicians sometimes consider it for specific non-dermatophyte fungal infections. However, this approach involves meticulous patient evaluation and must be accompanied by informed consent to ensure safety and efficacy.

Moreover, healthcare practitioners often turn to griseofulvin for recurrent systemic dermatophyte infections. This versatility underlines its importance in ongoing clinical guidelines that recommend griseofulvin as a suitable second-line option for patients with limited alternatives, thus broadening its therapeutic scope.

Griseofulvin Cream and Dosage Considerations

Griseofulvin is available in a variety of formulations, including tablets and oral suspensions. The recommended dosages typically vary depending on the type of tinea infection being treated:

• Tinea capitis, tinea corporis, tinea pedis: 500-1000mg daily.
• Tinea unguium: Higher doses may be required over longer treatment durations, often lasting several months.

For children, the dosage is particularly tailored to their weight, commonly set at 10-20mg/kg per day. This careful consideration allows for effective treatment while minimising the risk of side effects, making griseofulvin an accessible option for families.

Interestingly, griseofulvin cream is an option, adding to the number of ways it can be administered. While it's less common in practice, the cream is effective for localized infections and can be a great alternative for patients with adherence issues when taking oral medication.

Common Side Effects and Monitoring

Like any medication, griseofulvin comes with its set of potential side effects. Commonly reported adverse effects include headache, dizziness, and gastrointestinal disturbances like nausea and vomiting. Patients should also be aware of photosensitivity reactions that may occur, necessitating precautions against sun exposure.

For those with more significant health concerns, such as liver impairment or lupus, close monitoring is recommended. Regular check-ups help ensure that any complications can be identified and addressed promptly. Such vigilance is particularly necessary as griseofulvin interacts with other medications, making patient monitoring even more critical.

Summary of Griseofulvin's Efficacy

Griseofulvin remains a staple in the treatment of tinea infections, effectively targeting dermatophytes. Its role extends beyond conventional uses, and clinical judgment guides its application in off-label situations. The ongoing assessment of its efficacy and safety will help maintain griseofulvin's position as a reliable antifungal choice.

Delivery Information

City	Region	Delivery Time
Sydney	New South Wales	5–7 days
Melbourne	Victoria	5–7 days
Brisbane	Queensland	5–7 days
Perth	Western Australia	5–7 days
Adelaide	South Australia	5–7 days
Hobart	Tasmania	5–9 days
Canberra	Australian Capital Territory	5–7 days
Gold Coast	Queensland	5–9 days
Newcastle	New South Wales	5–9 days
Wollongong	New South Wales	5–9 days
Cairns	Queensland	5–9 days
Geelong	Victoria	5–9 days
Central Coast	New South Wales	5–9 days
Sunshine Coast	Queensland	5–9 days